Premium
Use of the polymeric matrix as internal standard for quantitation of in vivo delivery of tetracycline HCI from Actisite® tetracycline fiber during periodontal treatment
Author(s) -
Litch Joyce M.,
Encarnacion Myriam,
Chen Susan,
Leonard Joe,
Burkoth Terry L.
Publication year - 1996
Publication title -
journal of periodontal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 83
eISSN - 1600-0765
pISSN - 0022-3484
DOI - 10.1111/j.1600-0765.1996.tb00518.x
Subject(s) - tetracycline , tetracycline hydrochloride , dentistry , gingival and periodontal pocket , periodontitis , fiber , tetracycline antibiotics , matrix (chemical analysis) , chemistry , in vivo , antibiotics , biomedical engineering , medicine , chromatography , biology , microbiology and biotechnology , biochemistry , organic chemistry
Actisite® (tetracycline hydrochloride) periodontal fiber is a 23 cm monofilament containing 12.7 mg tetracycline HCI homogeneously dispersed in a polymer. This product sis indicated as an adjunct to scaling and root planing to reduce pocket depth and bleeding on probing in patients with adult periodontitis. The sustained‐release system, placed in the periodontal pocket for 10 d, releases the antibiotic through mechanisms of diffusion and osmosis. A study was conducted in 13 patients with moderate to severe adult periodontitis to evaluate the amount of tetracycline HCI released during therapy (based on residual drug content). Fibers placed in the pocket remained in place for an average of 9 d. Each patient had 1–4 teeth treated with fiber therapy. At the termination of therapy samples from 29 teeth were retrieved and analyzed. The amount of matrix polymer was used as an internal standard for the quantitation of tetracycline, eliminating any uncertainties with respect to recovery or contamination. An average of 31 % (SD 9%) of the tetracycline HCI content was released from the fiber during the treatment period. No single fiber had less than 50% of the original drug remaining. The study demonstrated that a substantial amount of the tetracycline remains in the Actisite® fiber at removal (about 70%), which indicates that substantial drug concentrations are maintained in the pocket for the duration of treatment.